Navigation Links
Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
Date:9/18/2007

NEW YORK, Sept. 18 /PRNewswire/ -- iiBIG is pleased to announce the never- before assembly of Global Cancer Experts at the 2008 Global Cancer Congress: Lighting the Onco-Pipeline -- Innovations in Stem Cell, Biomarker, Chemistry & Novel Therapeutic R&D, January 28-29, 2008 in Tampa, Florida. iiBIG is particularly pleased to join forces with our Florida affiliates from University of South Florida, University of Florida, Shands Cancer Center, Scripps Florida, and the other Florida cancer and academic institutes along with our nationally recognized distinguished faculty at this cutting-edge event.

This event will be the torchbearer to the most significant advances in cancer research, new therapies and novel approaches in the "War against Cancer". The program features a 2-track forum, with over 30 speakers, comprising plenary keynotes, lectures, panel sessions, roundtable discussions, interactive conversations with faculty and delegates, and actionable networking opportunities with leaders in various aspects of cancer research.

Distinguished Executive Speaking Faculty:

David L. Keefe, M.D.

James M. Ingram Professor and Chairman of the Department of Obstetrics and

Gynecology

University of South Florida

George Church, Ph.D.

Director of the Center for Computational Genetics, Director of the

Department of Genetics

Harvard-MIT Division of Health Sciences & Technology and Harvard Medical

School, Harvard University

William G. Thilly, Sc.D.

Professor of Biological Engineering

MIT

David J. Newman, Phil Sc.,

Chief, Natural Products Branch

National Cancer Institute (NCI)-FCRDC

James L. Sherley, M.D., Ph.D.

Senior Scientist

Regenerative Biology and Cancer Programs

Boston Biomedical Research Institute

Edward Scott, Ph.D.

Director of the UF Program in Stem Cell Biology and Regenerative Medicine

University of Florida

Gary D. Smith, Ph.D.,

Associate Professor, Departments of OB/GYN, Physiology, and Urology

Director: Reproductive Sciences Program, University of Michigan

James D. McChesney, Ph.D.,

CSO, Natural Products Chemistry

Tapestry Pharmaceuticals, Inc.

Tomi Sawyer, Ph.D.,

Senior Director, Department of Chemical Sciences

Pfizer Global R&D

Michael Nickerson

Director Genomic Research Division

Transgenomic Labs

Dalia Cohen, Ph.D.

Executive Vice President, Head of Global Research and Development

Rosetta Genomics, Ltd.

Gregg B. Fields, Ph.D.,

Professor and Chair, Department of Chemistry & Biochemistry

Florida Atlantic University

Chris Liang, Ph.D.

Scientific Director I, Translational Research Institute

Scripps Florida

Marilyn A. Apfel, Ph.D.

Co-founder and President

xFDA, LLC

Julia H. Riley, DVM, MS,

Diplomate American College Veterinary Pathologists, Diplomate American

Board Toxicology, Heads the Biologics Division, Toxicologist

xFDA, LLC

Ahsan Awan, JD, MBA,

Chief Executive Officers

Global CINRG, Inc.

Bernard Munos, Ph.D.,

Advisor, Corporate Strategy

Eli Lilly and Company

Stephen Chakoff

President & CEO

CHS Resources LLC

Jean-Claude Bystryn, M.D.

CEO & CSO

NeoVac

Glenn Batchelder

President and CEO

BIND Biosciences, Inc., latest Robert Langer, Ph.D. - MIT, Nanotechnology

Company

Christopher Milne, D.V.M., M.P.H., J.D.

Associate Director

Tufts Center for Drug Development

Mark Newman, Ph.D.

Senior Vice President, Global Research and Development Laboratories

Pharmexa-Epimmune

AGENDA TOPICS:

Some of the conference topics to be addressed (but are not limited to) include:

-- Integrative BioPharma Oncogenomics Standardizing Genetic Analysis

-- Drug Discovery Breakthroughs-Promising Compounds

-- Stem Cell Biology & Genetic Integrity

-- Interplay between Cancer & Stem Cells

-- Immunology

-- Micro-Tumor-Environment

-- Proteomic Biomarkers - Molecular Diagnostics: Earlier Detection and

Customizing Care

-- Therapeutic Vaccines Advancements

-- Multi-Drug Interaction - Drug Safety

-- Cancer Susceptibility, Resistance, and Systemic Changes

-- New Drugs Showing Real Promise

-- C-Team - Business Collaboration & Alliances between academia,

government, industry, foundations, regulatory, and private investment

resources - The Real Scenarios!

-- Biotech Showcase: Visit with 5 exciting young biotechnology companies*

in the cancer marketplace - The Real Light Makers

SPEAKING OPPORTUNITIES: Topic abstracts and speaker profiles will be accepted for consideration.

For more information, please contact Shelley Amster, VP, Pharmaceutical & Life Sciences Conferences, iiBIG, at 978-371-5901 or Shelleya@iibig.com.

SPONSORSHIP OPPORTUNITIES: For information on available sponsorship and exhibiting opportunities, please contact Kellie Swanstrom, VP Business Development, iiBIG, at 973-571-0867 or kellies@iibig.com.

FOR CONFERENCE UPDATES AND REGISTRATION INFORMATION:

Please visit: http://www.iibig.com/P0801

Call: 212-300-2523

E-mail: info@iibig.com


'/>"/>
SOURCE iiBIG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Cooper Lighting picks RedPrairie solutions
2. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
3. The state of global biotech: An Ernst & Young perspective
4. Doyle announces new energy, global warming policies
5. Lucigen Corp. enters global licensing agreement
6. Global information firm reaches diverse markets
7. Work-life imbalance - A global problem getting worse
8. Leading global Big Pharma companies of 2005
9. Learning to swim in the global talent pool
10. Federal and global guidelines on stem cell research offer a level playing field
11. Midwest life-science company Perrigo globalizes under the radar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):